EUVIMEDEUVIMED entdecken
Crossref

Preclinical Assessment and Tissue Distribution of Vodobatinib, a Third Generation BCr-Abl 1 Inhibitor

Sandeep Kaddare, Rama Murthi Bestha, Niranjan Veerla, Keerthana Madipelli, Ashok Zakkula, Sreekanth Dittakavi iD, Ramesh Mullangi iD

Drug Research · 01.09.2026 · 76 (07) · 170-178

DOI: 10.1055/a-2877-4153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Research, erschienen am 01.09.2026. Verfasst von Sandeep Kaddare und 6 weiteren Autor:innen. Beteiligte Einrichtung: LAXAI Life Sciences Pvt Ltd, Hyderabad, India. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Fusion Proteins, bcr-abl. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vodobatinib (K0706) is a novel, orally bioavailable Bcr-Abl 1 tyrosine kinase inhibitor designed to overcome resistance mutations such as T3151 in chronic myeloid leukemia. While its clinical efficacy and safety are under investigation, there is limited information on vodobatinib preclinical absorption, distribution, metabolism, and excretion properties and tissue distribution. The objective of this study is to evaluate vodobatinib solubility in phosphate buffer and biorelevant media, metabolic stability in liver microsomes and hepatocytes across species, permeability using MDCK-MDR1 cells, plasma protein binding via equilibrium dialysis, CYP phenotyping and CYP inhibition. Tissue distribution was assessed in male Sprague–Dawley rats following oral administration (2.0 mg/kg), with plasma and tissue samples collected over a 24-hour period. Vodobatinib exhibited poor solubility in phosphate buffer (2.5 µM), but showed improved solubility in biorelevant media. It demonstrated high metabolic stability in liver microsomes and hepatocytes of rats and dogs, with moderate stability in humans. Permeability studies indicated low efflux liability. Plasma protein binding was extensive (>99.8%) across species. Metabolism was primarily mediated by CYP3A4 (≈70%), with minor involvement from CYP2C19 and CYP2D6. CYP inhibition was weak to moderate, suggesting a low potential for drug–drug interactions. Vodobatinib showed high distribution to the liver, intestines, and kidneys, with low brain penetration. Vodobatinib demonstrates a favorable preclinical absorption, distribution, metabolism, and excretion profile, with high metabolic stability, minimal efflux liability, and selective tissue distribution. These findings support its continued clinical development in chronic myeloid leukemia and potentially other Bcr-Abl 1 driven malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsFusion Proteins, bcr-ablAnimalsMaleDogsMicrosomes, LiverRatsRats, Sprague-DawleyHumansTissue DistributionMadin Darby Canine Kidney CellsHepatocytesAdministration, OralSolubilityProtein Binding

Substanzen

Protein Kinase InhibitorsFusion Proteins, bcr-abl

Autor:innen und Institutionen

  • LAXAI Life Sciences Pvt Ltd, Hyderabad, India.

ORCID-Profile: Sreekanth Dittakavi, Ramesh Mullangi

Zitieren

APA

Kaddare, S., Bestha, R. M., Veerla, N., Madipelli, K., Zakkula, A., Dittakavi, S., & Mullangi, R. (2026). Preclinical Assessment and Tissue Distribution of Vodobatinib, a Third Generation BCr-Abl 1 Inhibitor. Drug Research, 76(07), 170-178. https://doi.org/10.1055/a-2877-4153

Vancouver

Kaddare S, Bestha RM, Veerla N, Madipelli K, Zakkula A, Dittakavi S, et al. Preclinical Assessment and Tissue Distribution of Vodobatinib, a Third Generation BCr-Abl 1 Inhibitor. Drug Research. 2026;76(07):170-178. doi:10.1055/a-2877-4153

BibTeX
@article{Kaddare2026,
  author = {Kaddare, Sandeep and Bestha, Rama Murthi and Veerla, Niranjan and Madipelli, Keerthana and Zakkula, Ashok and Dittakavi, Sreekanth and Mullangi, Ramesh},
  title = {Preclinical Assessment and Tissue Distribution of Vodobatinib, a Third Generation BCr-Abl 1 Inhibitor},
  journal = {Drug Research},
  year = {2026},
  volume = {76},
  number = {07},
  pages = {170--178},
  doi = {10.1055/a-2877-4153}
}
Kostenlos starten →